Aktis Oncology

Aktis Oncology develops alpha-emitting radiopharmaceuticals for cancer. Its lead program targets Nectin‑4 in solid tumors like urothelial carcinoma.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2026
Stage of Initial Investment
Series B
Initial Investment Year
2024